Delivery Order SPE2DB20D1100-SPE2DB25FE1T7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,869.18 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count supply) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price, competitively awarded contract involves no set-aside designation and specifies Conshohocken, Pennsylvania as the place of performance. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 8, 2025, with a ceiling value of $3,831.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) valued at $10,304.26. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement practices. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a $48,882.83 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) with a performance location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-asides and carries an ultimate completion date of August 18, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $42,751.81. This non-set-aside delivery order is expected to be completed by August 1, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract represents a child award under the company's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Gemtesa 75 mg tablets (90-count packages) under a firm fixed-price contract with a ceiling value of $14,925.47. This non-set-aside award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order has an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order valued at $7,747.10 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90 count) on August 12, 2025, with completion scheduled for August 13, 2025. This competitively awarded, firm fixed price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order valued at $18,536.93 to AmerisourceBergen Drug Corp for 90-count supplies of Gemtesa 75 mg tablets. This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, represents a competitively awarded, non-set-aside contract requiring performance in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $12,290.03 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count supply) on July 23, 2025, with completion scheduled for July 24, 2025. This non-competitive delivery order utilizes firm fixed pricing and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Gemtesa 75 mg tablets (90-count packaging) with a ceiling value of $3,197.73. This firm fixed-price delivery order, which is expected to be completed by August 20, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026). The award was made through...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1T7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,661.12 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) on August 20, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and is being performed at the vendor's Conshohocken, Pennsylvania location. As a child order under a larger contract vehicle, this delivery supports the federal government's pharmaceutical supply requirements for military and healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX) valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including medications for diabetes, neurological conditions, pain management, and specialized medical commodities. The current delivery order for Gemtesa, a urological medication, exemplifies the company's role as a critical vendor fulfilling ongoing pharmaceutical procurement needs for the Department of Defense and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 8/20/25 |